Company Website:
http://www.genzyme.com
CAMBRIDGE, Mass. -- (Business Wire)
Genzyme,
a Sanofi company, announced today that selected artwork from Expression
of Hope III will be featured through a travelling exhibit and online
gallery. Expression of Hope is a global disease awareness program
featuring works of art created by the community of people affected by
lysosomal storage disorders (LSD). This unique program encourages anyone
affected by an LSD to create and submit a work of art that expresses
their experiences of living with these rare, inherited diseases.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150520005144/en/
The 25 piece Expression of Hope III exhibit will open today at Genzyme
Center in Cambridge, Mass. The exhibit will travel to patient meetings
and conferences around the world in 2015 and 2016. Initial exhibits
include the National Niemann-Pick Disease Foundation family conference
in Chicago, Illinois, the Niemann-Pick Disease Group – UK Family
Conference in the United Kingdom, and the Global Genes “Tribute to
Champions of Hope” Gala in California. Future exhibits are currently
being planned for the Asia-Pacific region and Latin America. All of the
168 artwork submissions, including the 25 exhibit selections, can be
viewed at www.expressionofhope.com.
Working in collaboration with patient advocacy organizations around the
world, Expression of Hope III received submissions from artists of all
ages and artistic ability, including family members, friends and
healthcare workers from over 20 countries. The exhibit artwork was
selected by a panel of professional artists from the Massachusetts area,
including Lesley University’s Expressive Therapies program, the
DeCordova Museum, Massachusetts College of Art and the Rocky Neck Arts
Colony. This is the third Expression of Hope campaign, with nearly 500
artwork submissions received since the program first launched in in 2006.
“Artistic expression transcends barriers created by geography, language,
physical ability and age,” said Genzyme’s Head of Rare Diseases, Richard
Peters, M.D., Ph.D. “By sharing these reflections of the human spirit
with the world, the Expression of Hope artists challenge and motivate
thousands of people to better understand the experience of living with
an LSD.”
Lysosomal storage disorders, also known as lipid storage disorders, are
a group of inherited metabolic conditions in which fatty materials
(lipids) accumulate in various cells and tissues in the body. People
with these disorders either do not produce enough of an enzyme required
to break down (metabolize) lipids, or they produce enzymes that do not
work properly. Over time, the build-up of lipids can lead to cellular
and tissue damage, particularly in the brain, peripheral nervous system,
liver, spleen, and bone marrow.Examples of LSDs include
Gaucher, Fabry, Pompe, MPS and Niemann-Pick diseases.
About Expression of Hope
Expression of Hope is a global program of inspiration and awareness
featuring works of art by the lysosomal storage disorder community. In
collaboration with LSD patient organizations around the world, Genzyme
launched the Expression of Hope program in 2006 to give those impacted
by lysosomal storage disorders (LSDs) the opportunity to raise awareness
of these rare genetic diseases. More than 100 patients and caregivers
expressed their unique stories through their original pieces of artwork.
Building on that initial success, Genzyme launched the second Expression
of Hope program in 2009, and once again the global community responded
with enthusiasm, creativity and insight. Our third Expression of Hope
program further reinforces the commitment of individuals affected by
lysosomal storage disorders to building awareness and expressing their
unique stories through art. www.Expressionofhope.com
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation.
All rights reserved.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms:
diabetes solutions, human vaccines, innovative drugs, consumer
healthcare, emerging markets, animal health and Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number
of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2014. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150520005144/en/
Contacts:
Genzyme Media Contact:
Lori Gorski, 617-768-9344
lori.gorski@genzyme.com
or
Sanofi
Investor Relations Contact:
Sebastien Martel, +33 (0) 1.53.77.45.43
IR@sanofi.com
Source: Genzyme
© 2024 Canjex Publishing Ltd. All rights reserved.